Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Rubraca
Pharma
FDA sends CRL to Clovis in last-gasp bid for Rubraca nod
The FDA has rejected Clovis' long-shot bid for approval of Rubraca as a first-line maintenance treatment for ovarian cancer patients.
Kevin Dunleavy
Jun 5, 2023 10:20am
With Clovis in Chapter 11, Swiss firm buys up Rubraca for $70M
Apr 7, 2023 10:56am
Clovis reveals even more regulatory troubles for Rubraca
Feb 13, 2023 10:34am
Clovis finally throws in the towel, files for bankruptcy
Dec 12, 2022 12:23pm
Loan default, Rubraca move inches Clovis closer to bankruptcy
Dec 5, 2022 10:25am
After GSK, FDA asks Clovis to restrict PARP drug's cancer use
Nov 17, 2022 9:10am
